Stocks pulled back Monday after logging their best five-day streak in 75 years last week.
As December begins, the stock market remains perched precariously between horrible economic news and continued announcements of more loan facilities and an expanding Fed balance sheet.
The Thanksgiving-week rally took the markets up 10 percent, and with a 28-percent gain, financials outperformed just about everything else. BlackRock's Bob Doll sees investors cashing in on those gains this week, and recommends a move to more defensive stocks.
U.S. stock index futures pointed to a lower open for Wall Street Monday after stocks logged their best five-day streak in 75 years last week, ahead of a week packed with data and economic policy decisions.
The markets closed out a negative and volatile month with a very positive Thanksgiving week. The Dow and S&P 500 had their best five-day gain since 1933 with the Dow up over 17% and the S&P up over 19% in the last five trading sessions.
Oaktree Asset Management's Robert Pavlik warns investors not to be misled by what appear to be attractive valuations on stocks.
While the stock market rebound may not last, it has come with something Wall Street hasn't seen in awhile—buying into a rally.
Does the Food and Drug Administration approve drugs anymore? Or are we seeing the lame-duck leadership at the agency punt any action over to the next administration?
While the recent surge may vanish quickly, it came with something Wall Street hasn't seen in awhile—buying into a rally.
As the market remains focused on Citi and the President-elect's midday cabinet announcement there are a few newsworthy things going on in biopharmaland.
Warren Buffett's Berkshire Hathaway sharply increased its stake in ConocoPhillips this spring and summer, accumulating a total of 84 million shares as of the end of the third quarter on September 30, according to Berkshire's just-released quarterly portfolio filing with the SEC.
As the market turmoil continues, companies that once sat at the top of the S&P 500 find themselves falling further and further down the list.
One of the weapons widely used to fight cholesterol might be more powerful than previously believed. Is there a trade here?
"Buy the dips"? Not according to Michael Yoshikami, who says investors need to buy companies with "sustainable businesses," which sell "very boring things," that are well managed and that have good cash flow.
Now is the time for long-term investors to jump in and build a portfolio of recognizable, brand-name companies, Robert Pavlik Chief Investment Officer Oaktree Asset Management told CNBC.
Cramer makes the call on viewers' favorite stocks.
Investors in alternative energy, technology and infrastructure could be among the biggest beneficiaries.
While bad for you, they're much-needed for the product makers. Plus, Cramer dishes on retail and credit cards.
Plus, Cramer offers young investors advice on which stocks they should consider buying and more.